<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768312</url>
  </required_header>
  <id_info>
    <org_study_id>HL_TSPR_301</org_study_id>
    <nct_id>NCT01768312</nct_id>
  </id_info>
  <brief_title>Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group</brief_title>
  <acronym>Cyclosporine</acronym>
  <official_title>A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic
      solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12
      weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety
      in Moderate to Severe Dry Eye Disease.

      - Corneal staining test, Ocular surface disease index (OSDI), Tear break up time (TBUT),
      Non-anesthetic Schirmer test
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>Administered 12 weeks after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>Administered 4, 8 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index (OSDI)</measure>
    <time_frame>Administered 4, 8, 12 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>Administered 4, 8, 12 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-anesthetic Schirmer test</measure>
    <time_frame>Administered 4, 8, 12 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>Administered 4, 8, 12 weeks after</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-sporin eye drop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine ophthalmic solution</intervention_name>
    <description>1 drop twice/day for 12 weeks to both eyes</description>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <arm_group_label>T-sporin eye drop</arm_group_label>
    <other_name>Restasis Eye Drops</other_name>
    <other_name>Tisporin Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  [Patients with moderate-to-severe ocular dry eye]

               1. The sum of corneal fluorescein staining score of 5 or higher (NEI Scale)

               2. Non-anesthetic Schirmer test value ≤ 5mm/5min patients at least one eye score
                  (Non-anesthetic Schirmer test value = 0/5min, nasal stimulation in the same eye,
                  Schirmer test value ≥ 3mm/5min)

               3. Screening both eyes, the corrected visual acuity is 0.2 or more

               4. Despite conventional treatment, the symptoms of dry eye signs (Artificial tear
                  eye drops, sympathetic nervous system stimulant agent, parasympathetic nerve
                  stimulant, etc.)

               5. Negative urine pregnancy test at the screening when women of childbearing age

               6. Medically reliable method of contraception in the case of all women of
                  childbearing age or menopause (1 year after the last menstrual period women)
                  Sterilization (eg, bilateral oophorectomy, hysterectomy) women of childbearing
                  age have not been effective contraception only if you participate in a clinical
                  trial may have been determined to be pregnant by examining whether the voice,
                  maintained during the entire clinical trial period shall that.

               7. Written consent voluntarily to participate in this clinical trial

        Exclusion Criteria:

          -  1) Screening visits in the previous 3 months (12 weeks) who participated in the
             clinical trials of cyclosporine eye drops, or if you used a cyclosporine ophthalmic
             solutions.

             2) The patients with systemic or ocular disorders affected the test results (ocular
             surgery, trauma, or disease)

               1. Abnormal eyelid function : Disoders of the eyelids or eyelashes

               2. Ocular allergies or currently under the treatment of allergic diseases of the eye
                  (topical ocular mast cell stabilizer, antihistamine use, etc.)

               3. Cicatricial keratoconjunctivitis caused by herpetic keratopathy, conjunctival
                  scarring (alkali damage, Steven-Johnson syndrome, cicatricial pemphigoid),
                  pterygium, pinguecula, lack of congenital lacrimal, neurogenic keratitis,
                  keratoconus, corneal transplantation 3) current or recent patients used dry eye
                  syndrome medications (topical or systemic) that may affect the status 4) The use
                  in clinical trials of drug hypersensitivity reactions in patients 5) patients
                  with contact lens 6) If you use or plan to use punctual plug within 4 weeks 7)
                  Lacrimal punctual occlusion surgery patients 8) Ocular surgery within 3 months
                  (12 weeks) 9) Pregnant women, lactating, or planning to become pregnant 10) The
                  end of the lacrimal gland disease (Nasal stimulation Schirmer test value
                  &lt;3mm/5min) 11) History of malignancy 12) If you are receiving systemic steroids
                  or immunosuppressive treatment 15) In patients with severe renal failure (serum
                  creatinine more than 2.0 times the upper limit of normal) 16) In patients with
                  severe liver dysfunction (ALT or AST of more than 2.0 times the upper limit of
                  normal) 17) Alcohol or drug abuse 18) Pregnant women, lactating women 19)
                  Participating in a Clinical Trial patients who have participated in other
                  clinical trials within three months 20) Patients judged coexisting disease that
                  could interfere with the completion of the treatment or safety of this clinical
                  trial. Patients that other researchers are determined inadequately
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eun Mi Kim, Bachelor</last_name>
    <phone>(822)3489-6162</phone>
    <email>emkim@hanlim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The catholic university of Korea seoul st. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-Ku</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Yeon Hwang, master</last_name>
      <phone>(822)2258-1188</phone>
      <email>yeon424@paran.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

